PA22-176, SBIR, Phase I, Development of a SARS-CoV-2 emerging variant infectivity and immune evasion panel to quantify the efficacy of vaccine booster induced neutralizing antibodies.
NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES
· United States · $2.73M USD
We use cookies to keep your session secure, remember your preferences, and analyse site traffic with Google Analytics.
By continuing to use GrantFunds you agree to our
Privacy Policy
and
Terms of Use.